Odnass



Company Announcements:
(reported by the Company)
No items found
Elevator Pitch:

Odnass | Redefining Early Cancer Detection
Most cancers are discovered too late. Odnass is working to change that.
Each year more than 20 million people worldwide are diagnosed with cancer and nearly 10 million die, largely due to late detection. Earlier diagnosis remains one of the most powerful ways to improve survival and reduce the global burden of disease.

Odnass is developing a next-generation blood test designed to detect multiple cancers at their earliest, pre-symptomatic stage.
Unlike many liquid biopsy platforms that rely on complex sequencing workflows, the Odnass system focuses on the direct detection and analysis of cell-free DNA (cfDNA) in plasma using a proprietary protocol engineered for sensitivity, reproducibility, and cost efficiency.

What sets Odnass apart
-Direct cfDNA Detection – a simplified analytical protocol that reduces complexity and enables scalable testing.
-AI-Driven Predictive Modelling – Deep Machine Learning (DML) and Graph Neural Networks (GNN) integrate biological, clinical, and environmental factors to improve predictive accuracy.
-Secure Health Data Architecture – blockchain-supported infrastructure designed to ensure transparent and secure handling of sensitive medical data.
-Designed for Global Deployment – a cost-efficient platform intended for both advanced healthcare systems and underserved regions.

The Odnass platform is intended for population-level screening, monitoring of high-risk individuals, occupational exposure programs, and integration with traditional screening pathways.

Following the filing of its provisional patent in 2025, Odnass is advancing through its Proof-of-Concept phase, focusing on technology validation, expansion of its intellectual property portfolio, and strategic partnerships within the global diagnostics ecosystem.

Our vision: a world where cancer is detected earlier, treatment begins sooner, and survival outcomes improve for millions.
üì© velimir.p@odnass.com
üì© admin@odnass.com

Category: Blockchain, Health & biotech
URL: www.odnass.com
Operational Status:
ASX Listing Code (if applicable):
Year of Commencement: 2023
Address:

280 Bannister Rd, Unit 6, Canning Vale, Western Australia 6155, AU

State: Western Australia
Overseas Operations:
X:
Facebook:
Linkedin: https://au.linkedin.com/company/odnass-pty-ltd
Founders:
No items found
Awards won: